Subcutaneous Daratumumab Monotherapy for Patients with High-Risk Smoldering Multiple Myeloma By Ogkologos - December 18, 2024 987 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from the AQUILA study Source RELATED ARTICLESMORE FROM AUTHOR ESMO Announces 2026 Society Award Recipients Honouring Excellence in Cancer Research, Care and Leadership Adjuvant Olaparib Continues to Improve Multiple Outcomes in Patients with Germline BRCA1/2-associated High-Risk HER2-negative EBC EMA Recommends Refusing the Marketing Authorisation for Copper (64Cu) Oxodotreotide MOST POPULAR EMA Recommends Granting a Marketing Authorisation for Equidacent August 6, 2020 ESMO Asia Virtual Congress 2020, 20-22 November October 26, 2020 Cannabis, cannabinoids and cancer – the evidence so far September 1, 2021 Advanced and Metastatic Prostate Cancer Living Guideline June 11, 2026 Load more HOT NEWS BRAF/MEK Inhibition May Be a Viable Treatment Strategy Across the Majority... Can Some People with Breast Cancer Safely Skip Lymph Node Radiation? First Study to Demonstrate that PD1 Immune Checkpoint Blockade May Yield... How Cancer Survivors Can Overcome Common Challenges of Exercise After Treatment
